Patient diversity and inclusion are essential to rare disease research progress. Why?
Because people with the same disease may experience it differently. With a US population comprised of 40% racial and ethnic minorities[1],it’s essential that clinical trials reflect a variety of lived experiences, as well as characteristics like ethnicity, age, and gender, so that all communities can benefit from medical advancements.
But several logistical and socio-economic barriers make patient enrollment for already narrowly-targeted clinical trials near impossible.
Download this white paper today to explore the obstacles biopharma leaders and researchers face, along with innovative strategies that help broaden their paths to more diverse patients for clinical trials. Download today for strategies that will help you:
- Identify the logistical, economic, and social barriers that limit access to rare disease trials to position your team to avoid them.
- Leverage advocacy groups as critical stakeholders to improve access to genetic counseling, testing, and trial participation.
- Apply innovations like virtual health and remote data collection to break down barriers and widen patient eligibility.
- Effectively engage underrepresented patient populations, including non-English speakers and those in remote locations.
More inclusive clinical trials not only reflect the true diversity of the population, but also speed up patient recruitment and lead to faster approval and availability of life-saving treatments.
Take the First Step Toward Inclusive Research
Download your free copy of “Diversity and Inclusion in Rare Disease Clinical Research” and learn how to build stronger, more inclusive clinical trials that benefit both patients and drug development outcomes.
